With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.

Markets reflect a widespread belief that the US president always chickens out on trade measures. AstraZeneca’s plan to invest $50 bln stateside implies that sector-specific levies are inevitable. The ...